Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.
about
The Role of PPARs in CancerAdvances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and diseaseMutagenicity of the peroxisome proliferators clofibrate, Wyeth 14,643 and di-2-ethylhexyl phthalate in the lacZ plasmid-based transgenic mouse mutation assayClofibrate-induced gene expression changes in rat liver: a cross-laboratory analysis using membrane cDNA arrays.Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens.Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2Inhalation delivery of proteins from ethanol suspensionsUnravelling an epigenetic puzzle juxtaposition of peroxisomes and chromosomes in mitotic hepatocytes following methyl clofenapate administration to rats.A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.Cell death and cell proliferation in the control of normal and neoplastic tissue growth.The Role of PPARα Activation in Liver and Muscle.The toxicology of perfluorooctanoate.Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesisXenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicitiesImplications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis.Tetradecylthioacetic acid increases hepatic mitochondrial β-oxidation and alters fatty acid composition in a mouse model of chronic inflammationPeroxisome proliferators and peroxisome proliferator-activated receptor alpha: biotic and xenobiotic sensingGenomics and the search for novel biomarkers in toxicology.A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis.Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsThe human relevance of information on carcinogenic modes of action: overview.PPARalpha agonist-induced rodent tumors: modes of action and human relevance.The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genesPeroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferationApplying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene.Mono-(2-ethylhexyl) phthalate (MEHP) promotes invasion and migration of human testicular embryonal carcinoma cellsRole of oxidative stress in peroxisome proliferator-mediated carcinogenesis.Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation.Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate.Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.Bioavailability of therapeutic proteins by inhalation--worker safety aspects.Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling.Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet.Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes.Clofibrate pretreatment in mice confers resistance against hepatic lipid peroxidation.
P2860
Q21342955-E448D731-F1B3-4D1E-BF32-DCC46571FEC0Q24803926-2FEC61B8-4F73-4E85-8D46-8C370D6C010AQ24806937-ACA02604-15D4-4CAF-A837-24ADDE6DD245Q24811528-72B1D153-3CD1-4F08-BEF3-B1EBFA4152A9Q24812167-DE752212-C45B-42F1-A82E-E7B76FDEBFDCQ24816154-49871872-5AFC-4239-8FE7-E9587B8EA223Q28217612-1276D458-DF19-4740-8AD5-9137A96F12E9Q28398029-F9BB3B87-9C42-45AC-9B7F-84AABD7A4C92Q33366865-D304425A-0964-4245-B35D-EE509B4D7856Q33569334-F379E9B6-A2F8-4977-99BF-B19252ED7AB9Q33947654-ADA3DED0-9073-45A5-89E6-0FAF6F87A397Q34106233-964D107E-7F05-4A51-9FE8-D013B7C01379Q34343282-CD3B8997-85A4-4E78-B572-EA313331E027Q34463834-C8BBCBCC-41A6-44D4-B3DB-2C23FAE1176BQ34565215-6231E3DB-3D8D-4125-9782-A4C0693BC909Q34625038-6EFDF3CB-7856-4224-84C8-9F7FE1BFC5BFQ34636543-933F6F6E-4B88-4A9D-A72E-57705C7B56E6Q35091569-2FE8AD51-7A8A-4148-915C-5DD0D3076A3CQ35098336-90F01C08-2D6C-4CC8-A9B9-59EDAC9B769FQ35140486-EA392258-AF68-4ACB-944F-CCA6FACFD3D0Q35222107-B89AA4B4-6C45-45CA-8488-222AF3CCAFDEQ35603973-ADAAE0A2-FE48-444A-A5ED-47BB6DB7F56EQ35631051-686502C0-665B-4C63-A663-5FCFCF8E1189Q35631058-276586C5-5CF3-425B-A695-45D007D6E28BQ35677612-21953500-4652-40D2-BC3A-006AEA2D07E8Q35857112-C33924C3-01EC-4FE6-BC37-9A4A2C833E85Q35961038-452E7A5B-0DF5-4573-8399-042143D41172Q36000661-B68F0DDB-86F7-425F-A05A-1C7511C92ACCQ36059868-46A41061-8339-4BA7-B8AF-09E0BBC7731BQ36104056-4C3173D5-E6C2-4798-BBEC-12752F30D1F9Q37121662-343CA3F1-B881-4AF8-A9A4-304D8BB5D6F1Q37231752-AE4AE8D0-DE82-4466-AC23-F7CE80B7188FQ37557621-E1ADD2A5-3571-41EC-A697-62F795B12B5FQ37916566-CC284083-23DC-45C8-8A65-3CB08175DBDCQ38158164-324E7CD2-330B-4D89-85D1-15D4338E9684Q38222723-0609BE7B-CEB1-4F70-A52A-B4B4A3B0433AQ38294966-A2916B4D-65C7-404C-82E0-3405B576A08EQ40560414-A2CA925A-1E72-4407-852B-014F81AC5C23Q40733813-ED802459-53DC-49A1-BC68-0D6A70380640Q40738280-A4CCE84A-061E-422F-BCD0-3AF05B3D2C9D
P2860
Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Mechanistically-based human ha ...... -induced hepatocarcinogenesis.
@en
type
label
Mechanistically-based human ha ...... -induced hepatocarcinogenesis.
@en
prefLabel
Mechanistically-based human ha ...... -induced hepatocarcinogenesis.
@en
P2093
P2860
P1476
Mechanistically-based human ha ...... -induced hepatocarcinogenesis.
@en
P2093
B M Elliott
C R Elcombe
I F Purchase
J D Tugwood
P2860
P304
P356
10.1177/096032719401300201
P478
13 Suppl 2
P577
1994-11-01T00:00:00Z